Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate
Novartis announced that The New England Journal of Medicine published data for PKC412 (midostaurin) demonstrating an overall response rate, defined as a major or partial response, of 60% (95% confidence interval, 49-70%; P<0.001) in patients with advanced systemic mastocytosis. June 29, 2016